MedTech Dive March 3, 2023
Nick Paul Taylor

Dive Brief:

  • The U.S. Food and Drug Administration rejected a clinical trial application from Elon Musk’s brain implant company on safety grounds last year, Reutersreports.
  • According to multiple anonymous sources, the FDA raised concerns about the device’s lithium battery, the potential for its wires to migrate across the brain and how it would be removed.
  • The rejection reportedly happened one year ago and the company, Neuralink, is still working to address the concerns. In November, Musk said in a presentation that the company hoped to enter the clinic within six months.

Dive Insight:

Musk founded Neuralink in 2016. Since then, the billionaire has made bold claims about the potential of the technology, pitching it as both a way...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: AI (Artificial Intelligence), FDA, Govt Agencies, Medical Devices, Technology
Related Articles:
Healthy Returns: Trump’s FDA pick Makary may be a relief for biotech and pharma, analysts say
The telehealth background of Trump's FDA pick: 6 notes
President-elect Trump's picks for CDC, FDA, surgeon general: 31 notes
Opinion: RFK Jr. and MAHA should champion a Marshall Plan for obesity
Trump picks Johns Hopkins surgeon to head FDA: 10 things to know

Share This Article